Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Initialising ...
Br-
-methyl-phenylalanine for tumor PET imagingHanaoka, Hirofumi*; Ohshima, Yasuhiro; Suzuki, Yurika*; Yamaguchi, Aiko*; Watanabe, Shigeki; Uehara, Tomoya*; Nagamori, Shushi*; Kanai, Yoshikatsu*; Ishioka, Noriko; Tsushima, Yoshito*; et al.
Journal of Nuclear Medicine, 56(5), p.791 - 797, 2015/05
Times Cited Count：18 Percentile：62.37(Radiology, Nuclear Medicine & Medical Imaging)Chinone, Shumpei*; Hanaoka, Yasushi*; Tokuhiro, Koji*; Nakatsubo, Koichi*; Amano, Masayuki*; Hase, Yoshihiro; Tanaka, Atsushi; Narumi, Issei
JAEA-Review 2006-042, JAEA Takasaki Annual Report 2005, P. 90, 2007/02
no abstracts in English
Re]Organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levelsUehara, Tomoya*; Koike, Miho*; Nakata, Hideo*; Hanaoka, Hirofumi*; Iida, Yasuhiko*; Hashimoto, Kazuyuki; Akizawa, Hiromichi*; Endo, Keigo*; Arano, Yasushi*
Bioconjugate Chemistry, 18(1), p.190 - 198, 2007/01
Times Cited Count：20 Percentile：55.17(Biochemical Research Methods)Renal localization of radiolabeled antibody fragments constitutes a problem in targeted imaging and radiotherapy. To estimate the applicability of the molecular design to metallic radionuclides, [Re]tricarbonyl(cyclopentadienylcarbonate)rhenium ([Re]CpTR-COOH) was conjugated with maleoyl-glycyl-lysine to prepare [Re]CpTR-GK. The cleavage of the glycyl-lysine linkage of the compound generates a glycine conjugate of [Re]CpTR-Gly. [Re]CpTR-GK was conjugated to thiolated Fab fragments to prepare [Re]CpTR-GK-Fab. The biodistribution of radioactivity after injection of [Re]CpTR-GK-Fab was compared with that of [Re]CpTR-Fab. [Re]CpTR-GK-Fab exhibited significantly lower renal radioactivity levels than did [Re]CpTR-Fab. The analysis of urine samples collected for 6 h postinjection of [Re]CpTR-GK-Fab showed that [Re]CpTR-Gly was the major radiometabolite. In tumor-bearing mice, [Re]CpTR-GK-Fab significantly reduced renal radioactivity levels without impairing the radioactivity levels in tumor. These findings indicate that the molecular design of radioparmaceuticals labeled with metallic radionuclides can be useful by using a radiometal chelate of high inertness and by designing a radiometabolite of high urinary excretion when released from antibody fragments following cleavage of a glycyl-lysine linkage. This study also indicates that a change in chemical structure of a radiolabel attached to a glycyl-lysine linkage significantly affected enzymes involved in the hydrolysis reaction.
Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Ono, Masahiro*; Hanaoka, Hirofumi*; Ishino, Seigo*; Hashimoto, Kazuyuki; Nishimura, Hiroshi*; Saji, Hideo*
Bioconjugate Chemistry, 16(4), p.751 - 757, 2005/07
Times Cited Count：62 Percentile：86.83(Biochemical Research Methods)Rhenium-186-1-hydroxyethylidene-1,1-diphosphonate (
Re-HEDP) has been used for the palliation of metastatic bone pain. Delayed blood clearance and high gastric uptake of radioactivity have been observed upon injection, due to the instability of Re-HEDP in vivo. In this study, on the basis of the concept of bifunctional radiopharmaceuticals, we designed a stable Re-mercaptoacetylglycylglycylglycine (MAG3) complex-conjugated bisphosphonate (Re-MAG3-HBP). After purification by HPLC, Re-MAG3-HBP was synthesized with a radiochemical purity of over 95%. In biodistribution experiments, the radioactivity level ofRe-MAG3-HBP in bone was significantly higher than that of Re-HEDP. Blood clearance of Re-MAG3-HBP was faster than that of Re-HEDP. In addition, the gastric accumulation of Re-MAG3-HBP radioactivity was lower than that of Re-HEDP. In conclusion, Re-MAG3-HBP is expected to be a useful radiopharmaceutical for the palliation of metastatic bone pain.
Ogawa, Kazuma*; Mukai, Takahiro*; Arano, Yasushi*; Hanaoka, Hirofumi*; Hashimoto, Kazuyuki; Nishimura, Hiroshi*; Saji, Hideo*
Journal of Labelled Compounds and Radiopharmaceuticals, 47(11), p.753 - 761, 2004/11
Times Cited Count：29 Percentile：61.59(Biochemical Research Methods)no abstracts in English
Chinone, Shumpei*; Hanaoka, Yasushi*; Tokuhiro, Koji*; Nakatsubo, Koichi*; Amano, Masayuki*; Hase, Yoshihiro; Tanaka, Atsushi; Narumi, Issei
no journal, ,
no abstracts in English
Br-labeled antibody fragments for reduction of non-target radioactivityHanaoka, Hirofumi*; Watanabe, Shigeki; Watanabe, Satoshi; Ohshima, Yasuhiro; Uehara, Tomoya*; Akizawa, Hiromichi*; Iida, Yasuhiko*; Ishioka, Noriko; Arano, Yasushi*; Endo, Keigo*
no journal, ,
no abstracts in English
Br-labeled amino acid derivative for PET imaging of tumorHanaoka, Hirofumi*; Watanabe, Shigeki; Tominaga, Hideyuki*; Ohshima, Yasuhiro; Watanabe, Satoshi; Yamada, Keiichi*; Arano, Yasushi*; Ishioka, Noriko; Endo, Keigo*
no journal, ,
no abstracts in English
evaluation of 
In labeled hippuric acid derivative with high urinary excretionSuzuki, Hiroyuki; Kanai, Ayaka*; Uehara, Tomoya*; Hanaoka, Hirofumi*; Arano, Yasushi*
no journal, ,
At]astato--methyl-L-phenylalanine (2-AAMP) as a novel radiopharmaceutical for internal radiotherapyOhshima, Yasuhiro; Suzuki, Hiroyuki*; Hanaoka, Hirofumi*; Watanabe, Shigeki; Watanabe, Satoshi; Watanabe, Naoyuki*; Tsushima, Yoshito*; Endo, Keigo*; Arano, Yasushi*; Ishioka, Noriko
no journal, ,
Br-bromo--methyl-L-phenylalanine as a novel Br-labeled PET tracerOhshima, Yasuhiro; Hanaoka, Hirofumi*; Suzuki, Yurika*; Yamaguchi, Aiko*; Watanabe, Shigeki; Uehara, Tomoya*; Nagamori, Shushi*; Kanai, Yoshikatsu*; Ishioka, Noriko; Tsushima, Yoshito*; et al.
no journal, ,
no abstracts in English
At labeled -methyl-L-phenylalanineSuzuki, Hiroyuki*; Ohshima, Yasuhiro; Hanaoka, Hirofumi*; Watanabe, Shigeki; Watanabe, Satoshi; Sasaki, Ichiro; Sakashita, Tetsuya; Arano, Yasushi*; Ishioka, Noriko
no journal, ,
no abstracts in English
